FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049231567> ?p ?o ?g. }

• W2049231567 endingPage "243" @default.
• W2049231567 startingPage "237" @default.
• W2049231567 abstract "BackgroundThe combination of inhaled corticosteroids and long-acting inhaled β2-adrenergic-agonists has become the standard therapy for many patients with moderate to severe persistent asthma. Whether the differences between budesonide/formoterol and fluticasone/salmeterol translate into differences in treatment outcomes in a real life setting is unknown.ObjectivesThis study compared the use of healthcare services between new users of budesonide/formoterol and fluticasone/salmeterol in a single inhaler between 2002 and 2004.MethodsA 12-month population-based retrospective cohort study using administrative health care databases was conducted. Asthma patients 16–65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol. The rate of emergency department (ED) visits for asthma, hospitalizations for asthma, claims for oral corticosteroids, and visits to a respiratory specialist were compared between the two groups using Poisson regression models. The mean number of doses of short-acting β2-adrenergic-agonists (SABA) per week was compared between the two groups using a linear regression model.ResultsUsers of budesonide/formoterol were found to be less likely to have an ED visit for asthma (adjusted RR = 0.72; 95% CI: 0.54–0.96), a hospitalization for asthma (adjusted RR = 0.50; 95% CI: 0.25–0.99), a claim for oral corticosteroids (adjusted RR = 0.83; 95% CI: 0.72–0.95), and use SABA (adjusted mean difference = − 1.1 dose per week; 95% CI: −1.7; −0.5) than patients treated with fluticasone/salmeterol.ConclusionOur study has found that subjects initiating ICS/LABA treatment with budesonide/formoterol had better outcomes than those initiating treatment with fluticasone/salmeterol. The combination of inhaled corticosteroids and long-acting inhaled β2-adrenergic-agonists has become the standard therapy for many patients with moderate to severe persistent asthma. Whether the differences between budesonide/formoterol and fluticasone/salmeterol translate into differences in treatment outcomes in a real life setting is unknown. This study compared the use of healthcare services between new users of budesonide/formoterol and fluticasone/salmeterol in a single inhaler between 2002 and 2004. A 12-month population-based retrospective cohort study using administrative health care databases was conducted. Asthma patients 16–65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol. The rate of emergency department (ED) visits for asthma, hospitalizations for asthma, claims for oral corticosteroids, and visits to a respiratory specialist were compared between the two groups using Poisson regression models. The mean number of doses of short-acting β2-adrenergic-agonists (SABA) per week was compared between the two groups using a linear regression model. Users of budesonide/formoterol were found to be less likely to have an ED visit for asthma (adjusted RR = 0.72; 95% CI: 0.54–0.96), a hospitalization for asthma (adjusted RR = 0.50; 95% CI: 0.25–0.99), a claim for oral corticosteroids (adjusted RR = 0.83; 95% CI: 0.72–0.95), and use SABA (adjusted mean difference = − 1.1 dose per week; 95% CI: −1.7; −0.5) than patients treated with fluticasone/salmeterol. Our study has found that subjects initiating ICS/LABA treatment with budesonide/formoterol had better outcomes than those initiating treatment with fluticasone/salmeterol." @default.
• W2049231567 created "2016-06-24" @default.
• W2049231567 creator A5071840675 @default.
• W2049231567 creator A5086712537 @default.
• W2049231567 creator A5088405436 @default.
• W2049231567 date "2009-02-01" @default.
• W2049231567 modified "2023-10-03" @default.
• W2049231567 title "Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol" @default.
• W2049231567 cites W1543855637 @default.
• W2049231567 cites W1555651758 @default.
• W2049231567 cites W1760629554 @default.
• W2049231567 cites W1795103282 @default.
• W2049231567 cites W1868621599 @default.
• W2049231567 cites W1903824044 @default.
• W2049231567 cites W1986695203 @default.
• W2049231567 cites W1996970874 @default.
• W2049231567 cites W1997013992 @default.
• W2049231567 cites W2013037468 @default.
• W2049231567 cites W2023060497 @default.
• W2049231567 cites W2025409168 @default.
• W2049231567 cites W208068470 @default.
• W2049231567 cites W2082606792 @default.
• W2049231567 cites W2095872176 @default.
• W2049231567 cites W2113634031 @default.
• W2049231567 cites W2128982205 @default.
• W2049231567 cites W2139099862 @default.
• W2049231567 cites W2145018753 @default.
• W2049231567 cites W2146091727 @default.
• W2049231567 cites W2149452009 @default.
• W2049231567 cites W2150746593 @default.
• W2049231567 cites W2165209634 @default.
• W2049231567 cites W2331287401 @default.
• W2049231567 cites W3142424398 @default.
• W2049231567 doi "https://doi.org/10.1016/j.rmed.2008.09.001" @default.
• W2049231567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18930647" @default.
• W2049231567 hasPublicationYear "2009" @default.
• W2049231567 type Work @default.
• W2049231567 sameAs 2049231567 @default.
• W2049231567 citedByCount "14" @default.
• W2049231567 countsByYear W20492315672012 @default.
• W2049231567 countsByYear W20492315672013 @default.
• W2049231567 countsByYear W20492315672014 @default.
• W2049231567 countsByYear W20492315672017 @default.
• W2049231567 countsByYear W20492315672018 @default.
• W2049231567 crossrefType "journal-article" @default.
• W2049231567 hasAuthorship W2049231567A5071840675 @default.
• W2049231567 hasAuthorship W2049231567A5086712537 @default.
• W2049231567 hasAuthorship W2049231567A5088405436 @default.
• W2049231567 hasBestOaLocation W20492315671 @default.
• W2049231567 hasConcept C118552586 @default.
• W2049231567 hasConcept C126322002 @default.
• W2049231567 hasConcept C2776042228 @default.
• W2049231567 hasConcept C2776136866 @default.
• W2049231567 hasConcept C2776719499 @default.
• W2049231567 hasConcept C2777450039 @default.
• W2049231567 hasConcept C2779028295 @default.
• W2049231567 hasConcept C2779871671 @default.
• W2049231567 hasConcept C2780261241 @default.
• W2049231567 hasConcept C2780724011 @default.
• W2049231567 hasConcept C2781212218 @default.
• W2049231567 hasConcept C42219234 @default.
• W2049231567 hasConcept C71924100 @default.
• W2049231567 hasConceptScore W2049231567C118552586 @default.
• W2049231567 hasConceptScore W2049231567C126322002 @default.
• W2049231567 hasConceptScore W2049231567C2776042228 @default.
• W2049231567 hasConceptScore W2049231567C2776136866 @default.
• W2049231567 hasConceptScore W2049231567C2776719499 @default.
• W2049231567 hasConceptScore W2049231567C2777450039 @default.
• W2049231567 hasConceptScore W2049231567C2779028295 @default.
• W2049231567 hasConceptScore W2049231567C2779871671 @default.
• W2049231567 hasConceptScore W2049231567C2780261241 @default.
• W2049231567 hasConceptScore W2049231567C2780724011 @default.
• W2049231567 hasConceptScore W2049231567C2781212218 @default.
• W2049231567 hasConceptScore W2049231567C42219234 @default.
• W2049231567 hasConceptScore W2049231567C71924100 @default.
• W2049231567 hasIssue "2" @default.
• W2049231567 hasLocation W20492315671 @default.
• W2049231567 hasLocation W20492315672 @default.
• W2049231567 hasOpenAccess W2049231567 @default.
• W2049231567 hasPrimaryLocation W20492315671 @default.
• W2049231567 hasRelatedWork W1970048937 @default.
• W2049231567 hasRelatedWork W1985655856 @default.
• W2049231567 hasRelatedWork W1989310269 @default.
• W2049231567 hasRelatedWork W2005698822 @default.
• W2049231567 hasRelatedWork W2024265404 @default.
• W2049231567 hasRelatedWork W2049231567 @default.
• W2049231567 hasRelatedWork W2086416159 @default.
• W2049231567 hasRelatedWork W2332556071 @default.
• W2049231567 hasRelatedWork W2407210537 @default.
• W2049231567 hasRelatedWork W2621439852 @default.
• W2049231567 hasVolume "103" @default.
• W2049231567 isParatext "false" @default.
• W2049231567 isRetracted "false" @default.
• W2049231567 magId "2049231567" @default.
• W2049231567 workType "article" @default.